Mydecine Innovations Group Included in First-Ever Psychedelics ETF

DENVER, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).

Go here to see the original:
Mydecine Innovations Group Included in First-Ever Psychedelics ETF

Related Posts